Loading...
•
Jun 30, 2023
Zura Bio Q2 2023 Earnings Report
Zura Bio reported financial results for the second quarter ended June 30, 2023.
Key Takeaways
Zura Bio reported cash and cash equivalents of $112.8 million as of June 30, 2023. R&D expenses were $28.2 million and G&A expenses were $5.7 million for the second quarter ended June 30, 2023.
Cash and cash equivalents were $112.8 million as of June 30, 2023.
The company anticipates that its cash and cash equivalents are sufficient to fund its planned operations through 2026.
R&D expenses were $28.2 million for the second quarter ended June 30, 2023.
G&A expenses were $5.7 million for the second quarter ended June 30, 2023.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...